Metformin is the lifelong partner in diabetes management: true or false?

Abstract

Get full access to this article

View all access options for this article.

References

Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin . N Engl J Med 2002;346:393-403.

Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009;374:1677-86.

Ratner RE , Christophi CA , Metzger BE et al. Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. J Clin Endocrinol Metab 2008;93:4774-9.

Ratner R. , Goldberg R. , Haffner S. et al. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care 2005;28:888-94.

Ramachandran A. , Snehalatha C. , Mary S. et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1) . Diabetologia 2006;49:289-97.

Zinman B. , Harris SB , Neuman J. et al. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet 2010;376:103-11.

Flegal KM , Carroll MD , Ogden CL , Johnson CL Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002;288:1723-7.

Ebbeling CB , Pawlak DB , Ludwig DS Childhood obesity: public-health crisis, common sense cure. Lancet 2002;360:473-82.

Iannuzzi A. , Licenziati MR , Acampora C. et al. Increased carotid intimamedia thickness and stiffness in obese children. Diabetes Care 2004; 27:2506-8.

10.

Adlerberth AM , Rosengren A. , Wilhelmsen L. Diabetes and long-term risk of mortality from coronary and other causes in middle-aged Swedish men. A general population study. Diabetes Care 1998;21:539-45.

11.

Scottish Intercollegiate Guidelines Network. Guideline for the management of diabetes. www.sign.ac.uk/guidelines/fulltext/116/index.html (accessed November 2010).

12.

Després JP , Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006;444:881-7.

13.

Kurukulasuriya R. , Banerji MA , Chaiken R. , Lebovitz H. Selective decrease in visceral fat is associated with weight loss during metformin treatment in African Americans with type 2 diabetes. Diabetes 1999; 48(suppl):A315.

14.

Campbell IW Comparing the actions of older and newer therapies on body weight: to what extent should these effects guide the selection of antidiabetic therapy? Int J Clin Pract 2010 ;64:791-801.

15.

Golay A. Metformin and body weight. Int J Obes ( Lond) 2008;32:61-72.

16.

Lugari R. , Dell’Annaa C. , Sarti L. et al. Effects of metformin on intestinal and pancreatic endocrine secretion in type 2 (non-insulin dependent) diabetes. Molecular & Cell Biology of Type 2 Diabetes and Its Complications. Front Diabetes 1998;14:161-3.

17.

Mannucci E. , Ognibene A. , Cremasco F. et al. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese non-diabetic subjects. Diabetes Care 2001;24:489-94.

18.

Zander M. , Taskiran M. , Toft-Nielsen MB et al. Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes. Diabetes Care 2001;24:720-25.

19.

Yasuda N. , Inoue T. , Nagakura T. et al. Enhanced secretion of glucagon-like peptide 1 by biguanide compounds . Biochem Biophys Res Comm 2002;298:779-84.

20.

Hinke SA , Kühn-Wache K. , Hoffmann T. et al. Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1. Biochem Biophys Res Comm 2002;291:1302-8.

21.

Fineman MS , Bicsak TA , Shen LZ et al. Effect on glycemic control of Exenatide (synthetic Exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003;26:2370-7.

22.

Morrison JA , Cottingham EM , Barton BA et al. Metformin for weight loss in pediatric patients taking psychotropic drugs. Am J Psychiatry 2002;159:655-7.

23.

Freemark M. , Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics 2001;107:E55.

24.

Atabek EA , Pirgon O. Use of metformin in obese adolescents with hyperinsulinemia: a 6-month, randomized, double-blind, placebo-controlled clinical trial. J Ped Endocrinol Metabol 2008;21:339-48.

25.

Park MIH , Kinra S. , Ward KJ , White B. , Viner RM Metformin for obesity in children and adolescents: a systematic review. Diabetes Care 2009; 32:1743-45.

26.

Jones KL , Arslanian S. , Peterokova VA et al. Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial. Diabetes Care 2002;25:89-94.

27.

UK Prospective Diabetes Study Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.

28.

Crowther CA , Hiller JE , Moss JR et al. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med 2005;352: 2477-86.

29.

HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 2008;358:1991-2002.

30.

Landon MB , Spong CY , Thom E. et al. A multicenter, randomized trial of treatment for mild gestational diabetes. N Engl J Med 2009;361: 1339-48.

31.

National Institute for Health and Clinical Excellence. Guideline CG63: Diabetes in pregnancy. London: NICE, 2008.

32.

Langer O. , Conway DL , Berkus MD et al. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med 2000;343:1134-8.

33.

Nathan DM , Buse JB , Davidson MB et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009 ;22:17-30.

34.

Gutzin SJ , Kozer E. , Magee LA et al. The safety of oral hypoglycemic agents in the first trimester of pregnancy: a meta-analysis. Can J Clin Pharmacol 2003;10:179-83.

35.

Bailey CJ, Campbell IW, Chan JCN, Davidson JA, Howlett HCS, Ritz P (eds). Metformin: the Gold Standard. A scientific handbook. Chichester: Wiley, 2007.

36.

Simmons D. , Walters BN , Rowan JA et al. Metformin therapy and diabetes in pregnancy. Med J Aust 2004;180:462-4.

37.

Rowan JA , Hague WM , Gao W. et al. Metformin versus insulin for the treatment of gestational diabetes . N Engl J Med 2008;358:2003-15.

38.

UK Prospective Diabetes Study Group. UK prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249-58.

39.

Turner RC , Cull CA , Frighi V. , Holman RR Glycaemic control with diet, sulphonylurea, metformin or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). JAMA 1999;281:2005-12.

40.

Melander A. , Folino-Gallo P. , Walley T. et al. Utilisation of antihyperglycaemic drugs in ten European countries: different developments and different levels. Diabetologia 2006;49:2024-9.

41.

Yki-Järvinen H. , Ryysy L. , Nikkilä K. et al. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. Ann Int Med 1999; 130:389-96.

42.

Douek IF , Allen SE , Ewings P. et al. Continuing metformin when starting insulin in patients with Type 2 diabetes: a double-blind randomized placebo-controlled trial. Diabet Med 2005;22:634-40.

43.

Lund SS , Tarnow L. , Astrup AS et al. Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes. Diabetes Obes Metab 2009;11:966-77.

44.

Lund SS , Tarnow L. , Astrup AS et al. Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study. PLoS One 2008;3:e3363.

45.

Jacobsen IB , Henriksen JE , Beck-Nielsen H. The effect of metformin in overweight patients with type 1 diabetes and poor metabolic control. Basic Clin Pharmacol Toxicol 2009;105:145-9.

46.

Lund SS , Tarnow L. , Frandsen M. et al. Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial. BMJ 2009;339:b4324.

47.

Kooy A. , de Jager J. , Lehert P. et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Ann Intern Med 2009;169:616-25.

48.

Giovannucci E. , Harlan DM , Archer MC et al. Diabetes and cancer: a consensus report . CA Cancer J Clin 2010;60:207-21.

49.

Currie CJ , Poole CD , Gale EA The influence of glucose-lowering therapies on cancer risk in type 2 diabetes . Diabetologia 2009;52:1766-77.